500 mcg Other Ingredients: Microcrystalline Cellulose, Hypromellose, Vegetable Stearate, and Salcaprozate Sodium
BPC-157 is a 15-residue pentadecapeptide, GEPPPGKPADDAGLV, CHNO, 1419.53 g/mol, CAS 137525-51-0
Patients typically report initial reduction in pain or improvement in mobility within 1 to 2 weeks of starting BPC-157, with substantial healing changes between weeks 4 and 8
Last reviewed: November 16, 2025 Routine administration of all age-appropriate doses of vaccines at the same visit, also known as coadministration, is acceptable for children, adolescents, and adults if there are no contraindications at the time of the healthcare visit
Beyond direct actin binding, TB-500 has been documented to engage integrin-linked kinase (ILK) and AKT signalling pathways, extending its activity into cell-survival and migration signalling biology